Abstract
Background/Objectives: To examine changes in patient-reported sexual function, self-compassion, and quality of life during vaginal dilator use among women undergoing gynecological brachytherapy for cervical cancer. This study was designed as a prospective, single-group, repeated-measures study. Methods: This study was conducted with 80 women receiving brachytherapy for cervical cancer between June 2025 and February 2026 in a hospital. Data were collected at three time points (Week 1, Week 4, and Week 12) using a Patient Information Form, the Self-Compassion Scale–Short Form (SCS-SF), the Female Sexual Function Index (FSFI), and the EORTC QLQ-C30. Descriptive statistics, group comparisons, and repeated measures ANOVA were used to analyze changes over time and associations between clinical characteristics and outcome variables. Results: Participants had a mean age of 52.98 ± 10.98 years, and most were married and postmenopausal. Vaginal dryness (77.5%) and sexual pain (96.3%) were highly prevalent at Week 1 (pre-dilator) assessment, after brachytherapy. FSFI scores showed a significant improvement over time (p < 0.001), increasing from 10.65 ± 8.78 at Week 1 (Pre-dilator) to 19.34 ± 4.65 at Week 12. Quality of life initially declined at Week 4 (45.52 ± 10.85) but increased substantially by Week 12 (90.31 ± 13.93). In contrast, self-compassion scores decreased over the follow-up period (p < 0.001). In exploratory analyses, FSFI scores were higher among married than single participants; other subgroup differences did not remain significant after correction for multiple testing. Conclusions: Patient-reported sexual function and quality of life scores increased over the 12-week follow-up period, whereas self-compassion scores decreased. However, in the absence of a control group and objective assessment of vaginal anatomy, these longitudinal changes cannot be attributed specifically to vaginal dilator use. Natural recovery following cancer treatment, supportive care, and other concurrent factors may also have contributed to the observed changes. In contrast, self-compassion scores decreased over time, suggesting that the psychosocial needs of these patients should also be addressed through holistic care approaches.
1. Introduction
Cervical cancer is among the most common malignancies affecting women worldwide and constitutes a substantial burden of morbidity, particularly in women of reproductive age [1]. A large proportion of patients with gynecological cancer are diagnosed at advanced stages; therefore, their treatment commonly involves a combination of radiotherapy and chemotherapy [2]. In locally advanced gynecological tumors, the standard treatment approach consists of external beam radiotherapy (EBRT) administered concurrently with chemotherapy, followed by intracavitary brachytherapy (BRT) [3].
Brachytherapy has evolved from low-dose-rate (LDR) brachytherapy requiring inpatient hospitalization to high-dose-rate (HDR) brachytherapy, which is most often delivered in an outpatient setting [4,5]. This treatment modality enables the delivery of high radiation doses directly to the tumor site while sparing surrounding healthy tissues and providing effective treatment with fewer applications [6]. Although BRT contributes significantly to treatment success, the use of ionizing radiation may lead to persistent and difficult-to-manage adverse effects that can negatively influence treatment outcomes. Radiotherapy-related adverse effects may occur early and persist for years [7].
Radiotherapy may disrupt vaginal structure, leading to reduced length, decreased lubrication, and loss of elasticity. As a result, patients may experience stenosis, dryness, and dyspareunia (painful sexual intercourse) [8,9,10]. Vaginal stenosis, defined as a narrowing of the vaginal canal, typically develops approximately three months after completion of treatment. It is commonly associated with sexual dysfunction, which adversely affects women’s quality of life and leads to both physical and psychological complications [11]. Studies have reported grade 1 vaginal stenosis in 11% and grade 2 vaginal stenosis in 15% of women [12]. Another study reported a 22.70% incidence of grade 3 vaginal stenosis over a 20-month follow-up period [13]. When all grades are considered, the overall prevalence approaches 22%. Pelvic pain has been reported in approximately 10% of women [14].
Survivors of gynecological cancer frequently experience psychological difficulties such as reduced libido, altered body image, and anxiety related to sexual performance. They may also experience difficulties maintaining previous sexual roles, emotional distancing from partners, and concerns regarding their partner’s sexual interest after treatment [15]. These physical, psychological, and social consequences can substantially impair sexual and health-related quality of life. Regarding vaginal dilator use, one study reported adherence rates of 13.50% two months after BRT and 10.20% at six months [14].
There are no standardized guidelines regarding the timing and duration of vaginal dilator use [16]. It has been suggested that dilator use should begin approximately 15 days after completion of pelvic radiotherapy to prevent adhesions in the vaginal mucosal walls. Continued use for up to one year after treatment completion has been shown to reduce the risk of vaginal stenosis [17,18]. However, psychological resistance to vaginal dilator use is well documented [19]. Although prospective evidence from the EMBRACE-I study confirms that regular dilation significantly reduces grade ≥2 stenosis risk [20], long-term compliance remains challenged by documented physical, informational, and psychosexual barriers [19,21].
Sexual rehabilitation after pelvic radiotherapy is multifaceted and is not limited to vaginal dilator use. It may also include resumption of sexual intercourse, use of vaginal moisturizers and water-based lubricants, vaginal hormonal therapy where appropriate, pelvic floor rehabilitation, and psychosexual counseling [8,11,21]. In this context, sexual activity may function both as a rehabilitation behavior and as a determinant of how sexual function is measured, since several FSFI domains can only be scored in women who have been sexually active. Furthermore, while self-compassion fosters psychological adaptation and quality of life in cervical cancer, its longitudinal trajectory during recovery remains unexplored [22].
This study aimed to examine changes in patient-reported sexual function, symptoms, self-compassion, and quality of life over a 12-week follow-up period among women who had undergone brachytherapy for cervical cancer and were advised to use vaginal dilators as part of routine post-treatment care. Specifically, the study focused on the longitudinal patterns of these patient-reported outcomes rather than evaluating the efficacy of vaginal dilator use. Vaginal anatomical measures, including vaginal length, width, and stenosis grade, were not assessed. By describing changes in sexual and psychosocial health outcomes during the post-brachytherapy follow-up period, this study seeks to provide insights into the experiences and care needs of these women and inform future controlled research.
2. Methods
2.1. Study Design, Setting, and Sample
The study was designed as a prospective, single-group, repeated-measures study. Vaginal dilator use was part of routine post-treatment care and was not allocated by the researchers; there was no control group, and no causal inference regarding dilator use was intended. The research was conducted between June 2025 and February 2026, with the participation of 80 patients diagnosed with cervical cancer. Data collection instruments were administered through face-to-face interviews with patients who agreed to participate in the study. The study was retrospectively registered on ClinicalTrials.gov (Identifier: NCT07547267). Prior ethical approval was granted by the Non-Interventional Ethics Committee of İzmir Demokrasi University (Date: 28 May 2025, No: 2025/4-4). The study was conducted strictly according to the approved protocol, with no modifications or deviations.
Vaginal dilator use has been incorporated into clinical practice following pelvic radiotherapy to address the risk of vaginal stenosis; however, the strength of evidence supporting its effectiveness remains limited [23]. In the clinical setting where this study was conducted, vaginal dilator use was recommended as part of routine post-treatment care. Therefore, the study was designed to evaluate changes in patient-reported outcomes over time without withholding routine clinical care from eligible participants. Vaginal length, width, and stenosis grade were not objectively assessed; outcomes were limited to patient-reported measures.
Female patients aged 18–72 years who had been diagnosed with cervical cancer, had received BRT, and met the eligibility criteria were included in the study. Detailed information about the study was provided to eligible participants, and written informed consent was obtained from all participants. The data collection process took approximately 20–30 min for each participant.
Participants received education regarding the importance of regular vaginal dilator use at the recommended frequency. To enhance adherence during the treatment process, periodic telephone reminders were provided. To ensure participant anonymity and maintain data confidentiality, all data were coded and stored in accordance with confidentiality principles.
Participants received education on vaginal dilator use, including its purpose, proper insertion technique, the importance of regular use, and measures to improve comfort and adherence. Published guidance commonly recommends initiating vaginal dilation after radiotherapy has been completed and acute inflammation has resolved, generally around four weeks after treatment. Recommendations regarding frequency and duration vary; some guidelines suggest use two to three times per week for 5–10 min per session. Participants were instructed to use the vaginal dilator two to three times per week for 5–10 min per session, in accordance with guideline recommendations. The smallest comfortable dilator is generally recommended initially, with gradual progression in size as tolerated and the use of a water-based lubricant. In the present study, participants were instructed to use the dilator according to the protocol provided by the clinical team. Periodic telephone reminders were used to reinforce the instructions and encourage adherence. The first study assessment (Week 1) was conducted during the second week after completion of brachytherapy, immediately before initiation of vaginal dilator use. The second assessment (Week 4) was performed four weeks after initiation of dilator use, and the third assessment (Week 12) was conducted twelve weeks after initiation. Although educational support and periodic telephone reminders were provided, participants’ actual adherence to the recommended dilator-use schedule was not systematically assessed. Specifically, individual frequency and duration of use, as well as the dilator size used and progression to larger sizes, were not recorded during follow-up. Therefore, adherence to the recommended protocol could not be quantified.
The target population consisted of approximately 110 cervical cancer patients treated annually at the relevant clinic. During the study period, data collection was completed with 80 patients who met the inclusion criteria and voluntarily agreed to participate. This sample represented 72.7% of the target population, indicating a high coverage rate.
The required sample size was estimated using G*Power version 3.1.9.7 for a repeated-measures analysis of variance (ANOVA) with a within-subjects factor. Assuming a medium effect size (Cohen’s f = 0.25), a significance level of α = 0.05, a statistical power of 0.80 (1 − β), three repeated measurements, a correlation of 0.50 among repeated measurements, and a nonsphericity correction of ε = 1.00, the estimated minimum required sample size was approximately 28 participants. The final sample consisted of 80 participants, exceeding the estimated minimum requirement.
This study was reported in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines.
2.2. Data Collection and Instruments
Following the acquisition of written informed consent, the data collection process was initiated. Participants were administered the Patient Information Form, the Self-Compassion Scale–Short Form (SCS-SF), the Female Sexual Function Index (FSFI), and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30, Version 3.0).
Oncologic treatment characteristics, including previous surgical procedures, chemotherapy, external beam radiotherapy (EBRT), and the number of brachytherapy sessions, were collected based on patients’ self-reports. The first assessment (Week 1) was conducted during the second week after completion of brachytherapy, immediately before initiation of vaginal dilator use. The second assessment (Week 4) was performed four weeks after initiation of vaginal dilator use, and the third assessment (Week 12) was performed twelve weeks after its initiation.
2.2.1. Participant Information Form
The Patient Information Form used in this study was developed by the researchers based on a review of the relevant literature and consisted of 17 items. The form comprised three sections: (1) sociodemographic characteristics (e.g., age, marital status, education level, and employment status), (2) treatment-related clinical characteristics (e.g., treatment modalities received, number of brachytherapy sessions, and follow-up duration), and (3) gynecological and sexual health characteristics (e.g., history of surgery, menopausal status, vaginal dryness, sexual activity, and treatment-related sexual changes) [24]. Sexual activity status was assessed at baseline using a self-reported question and categorized as active or inactive. Separately, participants were asked whether they had experienced pain and burning during sexual intercourse following cancer treatment. These symptoms were assessed independently of current sexual activity status and referred to participants’ post-treatment sexual experiences rather than necessarily indicating ongoing sexual activity at the time of assessment. In addition, participants were asked about whether they had received information regarding vaginal dilator use and their perceptions of its benefits. The variables included in this section were collected to provide a multidimensional assessment of gynecological and sexual health following pelvic radiotherapy and brachytherapy, as well as to evaluate the clinical and subjective Longitudinal changes during follow-up.
2.2.2. Self-Compassion Scale–Short Form (SCS-SF)
The Self-Compassion Scale–Short Form is a self-report instrument developed based on Neff’s (2003) theoretical model of self-compassion and is designed to assess an individual’s compassionate attitude toward oneself [25]. In the present study, the Turkish-adapted version of the scale, which consists of 11 items following the Turkish validity and reliability study, was used. The scale consists of items representing the core components of self-compassion—self-kindness, common humanity, and mindfulness—as well as their opposing dimensions, namely self-judgment, isolation, and over-identification [26]. The short form consists of 11 items, and participants rate their level of agreement with each statement using a 5-point Likert-type scale. The SCS-SF consists of 11 items rated on a 5-point Likert scale (1 = almost never to 5 = almost always); negative items [1, 4, 8- 11] were reverse-scored, and the total score ranges from 11 to 55, with higher scores indicating higher self-compassion. The same scoring algorithm was applied at all three assessments. In the original validation study of the short form, the internal consistency coefficient (Cronbach’s α) was reported as 0.86 [26]. In the present study, the Cronbach’s alpha coefficient was found to be 0.748.
2.2.3. Female Sexual Function Index (FSFI)
The Female Sexual Function Index (FSFI), developed by Rosen et al., is a 19-item multidimensional self-report instrument designed to comprehensively assess female sexual function across multiple domains [27]. The FSFI was administered to all participants at each of the three assessment time points, regardless of their baseline self-reported sexual activity status. For items with a response option indicating no sexual activity, this response was scored as 0, while the remaining response options were scored from 1 to 5, in accordance with the scoring procedure applied in this study. Baseline sexual activity status was assessed separately using the Participant Information Form and was not used as an exclusion criterion for FSFI administration or scoring. It consists of six subdomains (desire, arousal, lubrication, orgasm, satisfaction, and pain). Subscale scores are multiplied by predefined weighting factors to obtain a total score ranging from 2 to 36, with higher scores indicating better sexual function. The clinical cut-off score is 26.55 [28]. In the original validation study of the FSFI, the total internal consistency coefficient (Cronbach’s alpha) was reported as 0.97, while the subscale alpha values ranged from 0.82 to 0.94 [27]. In the present study, the total internal consistency coefficient of the FSFI was calculated as Cronbach’s α = 0.978, indicating that the scale demonstrated a high level of reliability in the sample of patients who had undergone brachytherapy due to cervical cancer.
2.2.4. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30, Version 3.0)
The EORTC QLQ-C30 is a 30-item instrument developed to assess quality of life in cancer patients and consists of functional scales, symptom scales, and a global health status/quality of life domain. The functional and symptom scales are rated on a 4-point Likert scale, whereas the global health status is assessed using a 7-point scale. Scores are standardized to a 0–100 scale according to the EORTC scoring manual. Higher scores on the functional scales and global health status indicate better quality of life [29]. The longitudinal analyses of the EORTC QLQ-C30 focused on global health status/quality of life and the five functional scales (physical, role, emotional, cognitive, and social functioning). Changes in these domains across the three assessment time points were examined using repeated-measures ANOVA and Bonferroni-adjusted pairwise comparisons. In the present study, the internal consistency coefficient of the EORTC QLQ-C30 global health status/quality of life scale was calculated as Cronbach’s α = 0.910.
2.3. Data Analysis
Data analysis was performed using IBM SPSS Statistics version 27. Descriptive statistics (frequency, percentage, mean, and standard deviation) were used to summarize the sociodemographic and clinical characteristics of the participants. For comparisons between two groups, either the independent samples t-test or the Mann–Whitney U test was applied according to the distributional properties of the data. Repeated measures analysis of variance (ANOVA) was used for longitudinal measurements. A p-value of less than 0.05 was considered statistically significant in all analyses. A post hoc power analysis was conducted using G*Power version 3.1.9.7 based on the final sample of 80 participants. Assuming a medium effect size (Cohen’s f = 0.25), a significance level of α = 0.05, three repeated measurements, a correlation of 0.50 among repeated measurements, and a nonsphericity correction of ε = 1.00, the estimated statistical power was approximately 99.9%. This indicated that the study had sufficient statistical power to detect medium-sized effects over time. Subgroup comparisons were conducted as exploratory analyses to examine potential differences in patient-reported outcomes according to participants’ sociodemographic and clinical characteristics. These analyses were not intended to provide confirmatory evidence. Given the number of comparisons performed, the findings were interpreted cautiously, considering the possibility of chance findings.
3. Results
A total of 80 patients were included in the study. The mean age of the participants was 52.98 ± 10.98 years, ranging from 34 to 72 years. Most participants were married (n = 62, 77.5%), whereas 18 (22.5%) were single. Regarding educational status, 30.0% were primary school graduates, 21.3% were illiterate, 21.3% had completed secondary school, 18.8% had completed high school, and 8.8% had a university degree or higher education. In terms of employment status, 71.3% of the participants were unemployed (Table 1).
Table 1.
Socio-demographic data of the participants (n = 80).
Regarding treatment characteristics, 68.7% of the patients had received surgical treatment, 51.3% had undergone chemotherapy, and 7.5% had received external beam radiotherapy (EBRT). Regarding brachytherapy (BRT), 47.5% of the patients had received five sessions, whereas 52.5% had received six sessions. A total of 55 patients (68.7%) had a history of surgery, while 25 (31.3%) had no history of surgery. The most common surgical procedure was total abdominal hysterectomy with bilateral salpingo-oophorectomy (65.0%). Most participants (81.3%) were postmenopausal, and 77.5% reported vaginal dryness. At baseline, 27 participants (33.8%) reported being sexually active, whereas 53 (66.3%) reported being sexually inactive. Regarding post-treatment sexual symptoms, 77 participants (96.3%) reported having experienced pain during sexual intercourse, and 52 (65.0%) reported having experienced a burning sensation during sexual intercourse. These symptoms reflect participants’ self-reported post-treatment experiences and do not necessarily indicate current sexual activity. Overall, 90.0% perceived vaginal dilator use as having a positive effect on their general health. Among participants, 15.0% (n = 12) perceived a reduction in vaginal dryness and 13.8% (n = 11) perceived a decrease in fear of sexual intercourse after using the vaginal dilator, while 7.5% (n = 6) reported that they did not perceive any vaginal adhesions. These items reflect participants’ self-reported perceptions and were not objectively verified (Table 1).
Table 2 presents a comparison of mean scores for the SCS-SF, FSFI, and EORTC QLQ-C30- Global Health Status/Quality of Life according to participants’ disease- and treatment-related characteristics. In the exploratory analysis according to marital status, married participants had nominally higher self-compassion scores (U = 361.000, p = 0.022) and higher FSFI total scores (U = 333.500, p = 0.004) than single participants.
Table 2.
Mean Scores of SCS-SF, FSFI, EORTC QLQ-C30, and Global Health Status/Quality of Life According to Participants’ Disease- and Treatment-Related Characteristics.
Week 1 scores represent the pre-dilator assessment conducted after completion of brachytherapy and do not reflect pre-treatment status. In the comparison based on gynecological surgery history, participants who had undergone surgery demonstrated significantly higher SCS-SF scores (t = 4.484, p < 0.001). However, no statistically significant differences were observed between the groups in terms of FSFI and global health status/quality of life scores (p > 0.05).
Regarding menopausal status, postmenopausal participants had significantly higher SCS-SF scores than premenopausal participants (U = 278.000, p = 0.009). In contrast, no significant differences were found between groups in FSFI and global health status/quality of life scores (p > 0.05).
Participants reporting vaginal dryness had significantly higher SCS-SF scores (U = 349.000, p = 0.015) and FSFI scores (U = 372.000, p = 0.018). In addition, sexually inactive participants exhibited significantly higher self-compassion scores compared with sexually active participants (U = 472.500, p = 0.013) (Table 2).
The total SCS-SF score decreased from 41.89 ± 6.79 at week 1 to 32.56 ± 3.94 at week 4 and further to 24.05 ± 6.26 at week 12. In contrast, the FSFI total score increased from 10.65 ± 8.78 at week 1 to 13.81 ± 5.09 at week 4 and to 19.34 ± 4.65 at week 12. According to repeated measures analysis of variance, the changes over time were statistically significant for both scales (self-compassion: F = 155.801, p < 0.001; FSFI: F = 41.784, p < 0.001) (Table 3).
Table 3.
Mean Scores of SCS-SF and FSFI.
Table 4 presents changes in participants’ quality of life and functional status over time. The global health status/quality of life score was 54.17 ± 11.25 at week 1, decreased to 45.52 ± 10.85 at week 4, and then showed a marked increase, reaching 90.31 ± 13.93 at week 12. Similarly, significant improvements were observed in physical, role, emotional, cognitive, and social functioning domains at week 12. According to repeated measures analysis of variance, the changes over time across all subdomains were found to be highly statistically significant (Table 4).
Table 4.
Longitudinal Changes in EORTC QLQ-C30 Functional and Global Health Status Scores Across Three Assessment Time Points.
Bonferroni-adjusted pairwise comparisons of the EORTC QLQ-C30 scales are presented in Table 5. Global health status/QoL decreased from Week 1 to Week 4 (mean difference = 8.65, 95% CI 4.35 to 12.94, p < 0.001) and then increased substantially by Week 12 (Week 1 vs. Week 12: −36.15, 95% CI −40.96 to −31.34; Week 4 vs. Week 12: −44.79, 95% CI −49.25 to −40.33; both p < 0.001). In contrast, all five functional scales were higher at each successive assessment. Scores increased from Week 1 to Week 4 (mean differences ranging from −16.46 for role functioning to −27.17 for physical functioning) and increased further from Week 4 to Week 12 (−31.25 for cognitive functioning to −38.75 for emotional functioning), with all comparisons significant at p < 0.001. The largest overall change between Week 1 and Week 12 was observed for emotional functioning (−65.52, 95% CI −71.17 to −59.87), followed by social (−60.63), physical (−60.58), cognitive (−57.92), and role functioning (−53.13). Negative mean differences indicate higher scores at the later time point.
Table 5.
Bonferroni-Adjusted Pairwise Comparisons of EORTC QLQ-C30 Scores Across Assessment Time Points.
4. Discussion
In this prospective repeated-measures study, changes in female sexual function, self-compassion, and quality of life were examined at three time points among 80 women treated with gynecological brachytherapy. Female sexual function and quality-of-life scores increased over the follow-up period, whereas self-compassion scores decreased. Vaginal dilator use has been reported to reduce fibrotic changes, preserve vaginal patency, and support long-term sexual function. Importantly, the Week 1 assessment was conducted after brachytherapy and before the initiation of dilator use, and therefore reflects a post-treatment, pre-dilator state that may already include acute radiation-related symptoms, rather than a pre-treatment oncologic baseline. As pre-treatment sexual function and quality of life were not measured, the changes observed between Week 1 and Week 12 cannot be interpreted as changes from pre-treatment status. They may partly reflect the natural resolution of acute treatment-related effects, as well as recovery after surgery, chemotherapy, and radiotherapy, in addition to the supportive care provided. Because dilator use was only one component of supportive care, and sexual activity was not standardized, the observed changes also cannot be separated from resumption of sexual activity or other rehabilitation measures.
Gynecological cancer treatments, particularly pelvic radiotherapy and brachytherapy, are associated with multidimensional impairments in female sexual function. Vaginal dryness, pain, loss of vaginal elasticity, and decreased libido are among the most frequently reported problems [30,31]. In previous studies, vaginal dilator use has been reported to reduce fibrotic changes, preserve vaginal patency, and support sexual function [32,33], the present study did not assess these outcomes. FSFI scores increased from 10.65 at Week 1 to 19.34 at Week 12, reflecting a change in self-reported sexual function during follow-up; however, the Week 12 mean remained below the commonly used cut-off for sexual dysfunction (26.55). This change should also be interpreted in the context of the study design, as sexual function may be influenced by treatment recovery, menopausal status, vaginal symptoms, and relationship factors. Because vaginal anatomical changes were not directly assessed, the observed increase in FSFI scores cannot be interpreted as evidence of anatomical recovery.
Sexual activity is a further important consideration. Two-thirds of participants were sexually inactive at Week 1, and the FSFI is primarily intended for sexually active women; scores in inactive women partly reflect the absence of sexual activity rather than sexual dysfunction alone. Furthermore, resumption of sexual activity during follow-up may itself have contributed to the increase in FSFI scores. However, sexual activity status was not reassessed at subsequent time points, preventing us from determining whether changes in FSFI scores reflected improvements in sexual function, changes in sexual activity, or a combination of both. Therefore, the observed increase in FSFI scores should be interpreted cautiously. Sexual rehabilitation after pelvic radiotherapy also encompasses resumption of intercourse, lubricants and moisturizers, hormonal therapy, pelvic floor rehabilitation, and psychosexual counseling; these components could not be separated in the present study [8,11,21].
In contrast to the improvements in sexual function and quality of life, self-compassion scores decreased over the follow-up period. This finding was unexpected, and its magnitude (about 18 points, or roughly 2.6 baseline standard deviations) is larger than would typically be expected for a trait-like construct within 12 weeks. Previous studies have indicated that physical recovery after cancer treatment does not always parallel psychological adaptation [34,35], and possible explanations in the present study include true changes in self-attitudes during recovery, changes in how participants interpret the items as their health status evolves (response shift), or repeated-measurement effects; however, none of these explanations were tested here. Body image, anxiety, depression, relationship adjustment, and treatment expectations were not measured, and the present data therefore cannot explain the decline. The finding requires replication in controlled studies with measures of these variables.
In exploratory, unadjusted analyses, married participants had higher FSFI and self-compassion scores than single participants, and only the difference in FSFI scores remained significant after correction for multiple testing. Marital status is likely to be closely related to sexual activity: women without a partner may be less likely to be sexually active, and FSFI total scores in sexually inactive women are lowered by the scoring of “no sexual activity” responses as 0 FSFI scores; among single participants, scores were close to the floor of the scale (6.56 ± 1.97). The FSFI difference between married and single participants may therefore partly reflect differences in sexual activity rather than in sexual function. Relationship quality, partner support, and sexual activity at each assessment were not assessed in sufficient detail to test this, and the difference in self-compassion could not be explained with the available data.
Participants with a history of gynecological surgery had higher self-compassion scores. Nevertheless, these associations should be interpreted cautiously because the subgroup analyses were exploratory and involved multiple unadjusted comparisons. The present study did not assess psychological resilience, emotional regulation, body acceptance, or coping strategies; therefore, these factors cannot be assumed to explain the observed differences. Furthermore, the cross-sectional nature of these subgroup comparisons does not allow conclusions to be drawn about the direction or mechanisms of these associations. Further studies using comprehensive psychosocial assessments are needed to investigate these findings. Postmenopausal participants also had higher self-compassion scores (nominal, not robust to correction). Menopausal status could not be separated from age or from surgical history, as most participants were postmenopausal (81.3%) and most had undergone hysterectomy with bilateral salpingo-oophorectomy (65.0%), and these differences cannot be explained with the data collected [33]. At first glance, the finding that participants reporting vaginal dryness had higher self-compassion and FSFI scores appears paradoxical. This result should be interpreted cautiously, as dilator adherence, symptom severity, and sexual activity were not measured in detail. One possible explanation is that symptom awareness may reflect greater engagement with self-care and a more mindful, accepting attitude toward one’s body, which may facilitate psychological adaptation during recovery [36].
Higher self-compassion scores were observed among sexually inactive participants compared with sexually active participants. Although this difference may be relevant to understanding the relationship between sexual activity and psychological well-being, the present study did not assess sexual performance anxiety, personal expectations regarding sexual activity, or other related psychosocial factors. The stress-reducing and protective effects of self-compassion may diminish negative body-related evaluations and thereby enhance psychological adjustment [37,38].
Quality-of-life scores declined between the Week 1 and Week 4 assessments but increased substantially by Week 12, while symptom scores decreased over the same period. These findings indicate marked changes in patient-reported outcomes during follow-up. However, the magnitude of these changes warrants careful interpretation, and the potential contributions of treatment recovery, supportive care, and other clinical or psychosocial factors cannot be distinguished within the present study design. The literature similarly reports that symptom burden increases in the early period following pelvic radiotherapy; however, quality of life improves over time with appropriate follow-up and supportive care [31,33,36]. The concurrent decrease in self-compassion alongside improvements in sexual function and quality of life may indicate that physical and psychological well-being do not necessarily progress in parallel [39,40,41], but this interpretation is tentative and was not directly tested.
Overall, these exploratory findings suggest that recovery after brachytherapy may involve different trajectories in sexual function, quality of life, and self-compassion. Self-compassion, sexual function, and quality of life varied according to factors such as marital status, menopausal status, symptom experience, and sexual activity. Therefore, in clinical practice, not only physical rehabilitation but also psychological support and self-compassion–based interventions should be integrated into the care process. Evidence regarding the effectiveness of vaginal dilator therapy after pelvic radiotherapy remains limited, and published studies have used heterogeneous protocols and outcome measures. Therefore, changes observed in the present study should be interpreted as changes occurring during the follow-up period rather than definitive evidence of a treatment effect. Controlled studies with clearly defined dilator protocols, adherence assessments, and longer follow-up periods are needed to clarify the contribution of vaginal dilator use to sexual function and vaginal health outcomes.
4.1. Limitations of the Study
This study has several limitations. The use of telephone interviews for a portion of the data collection may be considered a potential factor affecting participants’ level of concentration, particularly in the post-treatment period, when fatigue, pain, and fluctuations in overall health status are common. This may have led some participants to shorten their responses or provide more superficial answers. Consequently, variability in data depth and the level of detail in responses may have occurred.
In addition, the single-group, repeated-measures design and the single-center setting limit the causal interpretation of the findings and reduce their generalizability. The absence of a control group limits the ability to distinguish changes associated with vaginal dilator use from those related to natural recovery after treatment or other concurrent factors. Furthermore, no objective assessment of vaginal anatomy (length, width, stenosis grade) or of dilator adherence (frequency and duration of use) was performed; therefore, no conclusion can be drawn regarding the prevention of vaginal stenosis or the relationship between dilator use and the observed outcomes.
Although all participants received education regarding vaginal dilator use and periodic telephone reminders were provided, actual adherence to the recommended regimen was not systematically assessed. Individual frequency and duration of use, as well as dilator size and progression, were not recorded. Consequently, the extent of participants’ exposure to vaginal dilator use could not be determined. This limitation, together with the absence of a control group, restricts the ability to attribute the observed longitudinal changes specifically to vaginal dilator use. Therefore, the findings should be interpreted as changes occurring over the 12-week follow-up period rather than as definitive evidence of the effects of the intervention.
In addition, the relatively short 12-week follow-up period does not allow conclusions to be drawn about long-term sexual function or the prevention of vaginal stenosis. The interpretation of FSFI scores should also take into account that a substantial proportion of participants were sexually inactive. Finally, the lack of detailed control for potential confounding variables that may influence psychological adjustment—such as anxiety, depression, body image, and partner adjustment—restricts a more comprehensive mechanistic explanation of the relationships between self-compassion and sexual function. Sexual activity status was assessed using a self-reported question in the Patient Information Form only at baseline and was not independently reassessed during follow-up. Although the FSFI was administered at all three assessment time points, changes in sexual activity status during follow-up could not be directly established from the baseline information. Therefore, the potential influence of changes in sexual activity status on longitudinal FSFI scores should be considered when interpreting the findings.
Another limitation of this study is that certain oncologic treatment characteristics, including FIGO stage, histological subtype, and treatment intent, were not collected. Furthermore, information regarding previous oncologic treatments was based on patients’ self-reports rather than verified medical records. Therefore, some treatment modalities, particularly EBRT administered at other institutions, may have been underreported because patients might not have recalled or reported these treatments. Consequently, the reported proportion of patients who received EBRT may not accurately represent the actual treatment history of the cohort. These limitations should be considered when interpreting the findings, particularly in relation to the potential effects of oncologic treatment characteristics on vaginal and sexual health outcomes.
Another limitation concerns the completeness of clinical treatment data. Participants were referred from different healthcare institutions, which limited access to their complete treatment records. Although every effort was made to retrieve treatment-related information from available clinical records, documentation of previous and concurrent treatments, particularly EBRT, was not available for all participants. Consequently, the reported proportion of patients receiving EBRT may underestimate the actual proportion in the study population.
The substantial decrease in self-compassion scores, in contrast to the increase in sexual function and quality of life, could not be explained, as body image, anxiety, depression, relationship adjustment, and treatment expectations were not measured; the finding may also partly reflect measurement or response-shift effects and needs replication.
4.2. Clinical Implications
The findings of this study highlight the importance of addressing sexual function, quality of life, and psychological well-being during follow-up care for women treated with gynecological brachytherapy. Although improvements in sexual function and quality-of-life scores were observed over the 12-week follow-up period, these changes cannot be attributed solely to vaginal dilator use because the study did not include a control group. The observed decline in self-compassion scores further emphasizes the importance of considering psychological well-being alongside physical recovery.
Sexual rehabilitation after brachytherapy should be approached as a comprehensive process that includes patient education, vaginal dilator use, discussion of resuming sexual activity, symptom management (e.g., lubricants and moisturizers), and psychosexual support, rather than dilator use alone. Healthcare professionals, particularly nurses involved in oncology care and rehabilitation, should provide individualized education on vaginal dilator use and assess patients’ concerns, comfort, and adherence during follow-up. Regular assessment of sexual health and vaginal symptoms may help identify patients who require additional support. Furthermore, the findings suggest that psychological outcomes should also be considered when planning post-treatment care. Future studies should investigate whether psychosocial interventions, including mindfulness- and acceptance-based approaches, can support psychological adjustment in this population. A holistic, patient-centered, and multidisciplinary approach may help address the diverse supportive care needs of women recovering from cervical cancer treatment.
5. Conclusions
Female sexual function and quality-of-life scores increased over the 12-week follow-up period, whereas self-compassion scores decreased. Nevertheless, the mean FSFI score remained below the clinical cutoff at Week 12, indicating that sexual dysfunction had not resolved at the group level despite the observed improvement. These findings represent changes observed over time among women using vaginal dilators following brachytherapy. However, due to the absence of a control group, it is not possible to determine the extent to which these changes are attributable to vaginal dilator use rather than natural recovery or other concurrent clinical and psychosocial factors.
The findings highlight the importance of adopting a holistic approach to post-brachytherapy care that addresses both physical and psychosocial needs. In particular, regular assessment of sexual function, vaginal symptoms, quality of life, and psychological well-being may help identify patients requiring additional support. Education on vaginal dilator use should include not only technical instructions but also individualized counseling addressing patients’ concerns, comfort, and adherence.
Future controlled studies with longer follow-up periods, clearly defined dilator protocols, and objective assessments of vaginal health are needed to clarify the contribution of vaginal dilator use to sexual function and quality of life after gynecological brachytherapy.
Author Contributions
A.T.: conceptualization, data curation, formal analysis, writing—original draft, writing—review and editing, and visualization. V.K.: conceptualization, funding acquisition, investigation, writing—review and editing. D.Y.: data curation, funding acquisition, and investigation, resources, writing—review and editing. Ü.Ö.: conceptualization, funding acquisition, investigation, writing—review and editing. F.Ç.: conceptualization, funding acquisition, investigation, writing—review and editing. All authors have read and agreed to the published version of the manuscript.
Funding
This study was conducted as a specific research project supported by the “Scientific Research Projects Coordination Unit of Kocaeli University” under Grant No. TAD-2026-5043.
Institutional Review Board Statement
Ethical approval for the study was obtained from the Non-Interventional Ethics Committee of İzmir Demokrasi University with the decision dated 28 May 2025 and numbered 2025/4-4. Institutional permission was also obtained from the participating institution where the study was conducted. The research was carried out in accordance with the Declaration of Helsinki. All participants provided written informed consent.
Informed Consent Statement
Written informed consent has been obtained from the patients to publish this paper.
Data Availability Statement
The raw dataset containing sensitive patient health information and clinical questionnaire responses cannot be made publicly available due to ethical restrictions, patient privacy regulations, and institutional ethics committee guidelines to protect participant confidentiality. Therefore, data are available from the corresponding author upon reasonable request.
Acknowledgments
The authors would like to thank the Radiation Oncology Nursing Team of İzmir City Hospital for their valuable support during this study. AI-assisted tools were used solely for grammar and language refinement during the preparation of this article. No such tools were employed in data collection, data analysis, graphical abstract, the interpretation of findings, or the drafting of the article’s scientific content. The authors bear full responsibility for the entire scientific content and interpretations presented in the article.
Conflicts of Interest
The authors have no conflicts of interest.
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hanna, T.P.; Delaney, G.P.; Barton, M.B. The population benefit of radiotherapy for gynaecological cancer: Local control and survival estimates. Radiother. Oncol. 2016, 120, 370–377. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Zhang, B.; Zhang, S.; Sun, L.; Wu, Y.; Yang, Y. Characteristics of preplan-based three-dimensional individual template-guided brachytherapy compared to freehand implantation. J. Appl. Clin. Med. Phys. 2023, 24, e13840. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Banerjee, R.; Kamrava, M. Brachytherapy in the treatment of cervical cancer: A review. Int. J. Womens Health 2014, 6, 555–564. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Yang, X.; Ren, H.; Li, Z.; Fu, J. Brachytherapy for cervical cancer: From intracavitary to interstitial technique. Front Oncol. 2024, 14, 1442712. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Stewart, A.J.; Viswanathan, A.N. Current controversies in high-dose-rate versus low-dose-rate brachytherapy for cervical cancer. Cancer 2006, 107, 908–915. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Mordhorst, L.B.; Karlsson, L.; Bärmark, B.; Sorbe, B. Combined External and Intracavitary Irradiation in Treatment of Advanced Cervical Carcinomas. Int. J. Gynecol. Cancer 2014, 24, 1268–1275. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Barcellini, A.; Dominoni, M.; Dal Mas, F.; Biancuzzi, H.; Venturini, S.C.; Gardella, B.; Orlandi, E.; Bø, K. Sexual Health Dysfunction After Radiotherapy for Gynecological Cancer: Role of Physical Rehabilitation Including Pelvic Floor Muscle Training. Front Med. 2022, 8, 813352. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Delishaj, D.; Barcellini, A.; D’Amico, R.; Ursino, S.; Pasqualetti, F.; Fumagalli, I.C.; Soatti, C.P. Vaginal toxicity after high-dose-rate endovaginal brachytherapy: 20 years of results. J. Contemp. Brachyther. 2018, 10, 559–566. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kollberg, K.S.; Waldenström, A.C.; Bergmark, K.; Dunberger, G.; Rossander, A.; Wilderäng, U.; Åvall-Lundqvist, E.; Steineck, G. Reduced vaginal elasticity, reduced lubrication, and deep and superficial dyspareunia in irradiated gynecological cancer survivors. Acta Oncol. 2015, 54, 772–779. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Damast, S.; Jeffery, D.D.; Son, C.H.; Hasan, Y.; Carter, J.; Lindau, S.T.; Jhingran, A. Literature Review of Vaginal Stenosis and Dilator Use in Radiation Oncology. Pract. Radiat. Oncol. 2019, 9, 479–491. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Conway, J.L.; Gerber, R.; Han, K.; Jiang, H.; Xie, J.; Beiki-Ardakani, A.; Fyles, A.; Milosevic, M.; Williamson, D.; Croke, J. Patient-reported sexual adjustment after definitive chemoradiation and MR-guided brachytherapy for cervical cancer. Brachytherapy 2019, 18, 133–140. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Dankulchai, P.; Harn-utairasmee, P.; Prasartseree, T.; Nakkasae, P.; Trikhirhisthit, K.; Sittiwong, W.; Thephamongkhol, K.; Petsuksiri, J.; Apiwarodom, N.; Iampongpaiboon, P.; et al. Vaginal 11-point and volumetric dose related to late vaginal complications in patients with cervical cancer treated with external beam radiotherapy and image-guided adaptive brachytherapy. Radiother. Oncol. 2022, 174, 77–86. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kpoghomou, M.A.; Geneau, M.; Menard, J.; Stiti, M.; Almont, T.; Ghose, B.; Attal, J.; Delannes, M.; Huyghe, E.; Ducassou, A. Assessment of an onco-sexology support and follow-up program in cervical or vaginal cancer patients undergoing brachytherapy. Support Care Cancer 2021, 29, 4311–4318. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- de Freitas Corpes, E.; dos Anjos Gonçalves, G.; Caroline Andrade Oliveira, A.; da Silva Pacífico, V.; Christina Moura Barbosa Castro, R.; Cesar de Almeida, P.; Barbosa, I.M. Effects of Brachytherapy on Quality of Life And Functionality in the Treatment of Cervix Cancer. Cogitare Enferm. 2022, 27, 1–11. [Google Scholar] [CrossRef] [Scilit]
- Haddad, N.C.; Soares Brollo, L.C.; Pinho Oliveira, M.A.; Bernardo-Filho, M. Diagnostic Methods for Vaginal Stenosis and Compliance to Vaginal Dilator Use: A Systematic Review. J. Sex. Med. 2021, 18, 493–514. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Cerentini, T.M.; Schlöttgen, J.; Viana da Rosa, P.; La Rosa, V.L.; Vitale, S.G.; Giampaolino, P.; Valenti, G.; Cianci, S.; Macagnan, F.E. Clinical and Psychological Outcomes of the Use of Vaginal Dilators After Gynaecological Brachytherapy: A Randomized Clinical Trial. Adv. Ther. 2019, 36, 1936–1949. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Stahl, J.M.; Qian, J.M.; Tien, C.J.; Carlson, D.J.; Chen, Z.; Ratner, E.S.; Park, H.S.; Damast, S. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. Support Care Cancer 2019, 27, 1425–1433. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Lee, Y. Patients’ perception and adherence to vaginal dilator therapy: A systematic review and synthesis employing symbolic interactionism. Patient Prefer Adherence 2018, 12, 551–560. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kirchheiner, K.; Zaharie, A.; Smet, S.; Spampinato, S.; Chargari, C.; Haie-Meder, C.; Mahantshetty, U.; Šegedin, B.; Bruheim, K.; Rai, B.; et al. Association Between the Regular Use of Vaginal Dilators and/or Sexual Activity and Vaginal Morbidity in Locally Advanced Cervical Cancer Survivors: An EMBRACE-I Study Report. Int. J. Radiat. Oncol. 2025, 121, 452–464. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Morris, L.; Do, V.; Chard, J.; Brand, A.H. Radiation-induced vaginal stenosis: Current perspectives. Int. J. Womens Health 2017, 9, 273–279. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Liu, M.; Wang, J.; Luo, L. Self-Compassion Mediates the Relationship Between Social Support and Quality of Life in Cervical Cancer Patients: A Cross-Sectional Study. Cancer Manag Res. 2025, 17, 3039. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Miles, T.; Johnson, N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst. Rev. 2014, 2018, CD007291. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Chang, C.P.; Wilson, C.M.; Rowe, K.; Snyder, J.; Dodson, M.; Deshmukh, V.; Newman, M.; Fraser, A.; Smith, K.; Date, A.; et al. Sexual dysfunction among gynecologic cancer survivors in a population-based cohort study. Support Care Cancer 2022, 31, 51. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Neff, K.D. The Development and Validation of a Scale to Measure Self-Compassion. Self Identity 2003, 2, 223–250. [Google Scholar] [CrossRef] [Scilit]
- Raes, F.; Pommier, E.; Neff, K.D.; Van Gucht, D. Construction and factorial validation of a short form of the Self-Compassion Scale. Clin. Psychol. Psychother. 2011, 18, 250–255. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rosen, R.; Brown, C.; Heiman, J.; Leiblum, S.; Meston, C.; Shabsigh, R.; Ferguson, D.; D’Agostino, R., Jr. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J. Sex. Marital Ther. 2000, 26, 191–208. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wiegel, M.; Meston, C.; Rosen, R. The female sexual function index (FSFI): Cross-validation and development of clinical cutoff scores. J. Sex. Marital Ther. 2005, 31, 1–20. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Fayers, P.M.; Neil, A.; Bjordal, K.; Mogens, G.; Desmond, C.; Andrew, B. EORTC QLQ-C30 Scoring Manual: This manual Is Intended to Assist Users with Scoring Procedures for the QLQ-C30 Version 3 and Earlier, and the QLQ Supplementary Modules; European Organisation for Research and Treatment of Cancer: Brussels, Belgium, 2001. [Google Scholar]
- Arring, N.; Barton, D.L.; Reese, J.B. Clinical Practice Strategies to Address Sexual Health in Female Cancer Survivors. J. Clin. Oncol. 2023, 41, 4927–4936. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Guntupalli, S.R.; Sheeder, J.; Ioffe, Y.; Tergas, A.; Wright, J.D.; Davidson, S.A.; Behbakht, K.; Flink, D.M. Sexual and Marital Dysfunction in Women With Gynecologic Cancer. Int. J. Gynecol. Cancer 2017, 27, 603–607. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Tahseen, R.; Ahmed, Y.; Tariq, M.; Abrar, S.; Ali, N. Compliance and clinical efficacy of vaginal dilator after radiotherapy for cervical and endometrial malignancies. Ecancermedicalscience 2023, 17, 1545. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Law, E.; Kelvin, J.F.; Thom, B.; Riedel, E.; Tom, A.; Carter, J.; Alektiar, K.M.; Goodman, K.A. Prospective study of vaginal dilator use adherence and efficacy following radiotherapy. Radiother. Oncol. 2015, 116, 149–155. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Oliva, A.; García-Cebrián, J.M.; Calatayud, E.F.; Serrano-García, I.; Herraiz, M.A.; Coronado, P.J. A comparison of quality of life and resilience in menopausal women with and without a history of gynaecological cancer. Maturitas 2019, 120, 35–39. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Salafia, C.; Adamsons, K. Quality of life in breast cancer survivors: An ambiguous loss perspective. J. Fam. Theory Rev. 2025, 17, 549–564. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Smith, T.; Kingsberg, S.A.; Faubion, S. Sexual dysfunction in female cancer survivors: Addressing the problems and the remedies. Maturitas 2022, 165, 52–57. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Kristin, N.; Christopher, G. The Mindful Self-Compassion Worbook: A Proven Way to Accept Yourself; Guilford Publications: New York, NY, USA, 2018. [Google Scholar]
- Sommers-Spijkerman, M.; Trompetter, H.; Schreurs, K.; Bohlmeijer, E. Pathways to Improving Mental Health in Compassion-Focused Therapy: Self-Reassurance, Self-Criticism and Affect as Mediators of Change. Front Psychol. 2018, 9, 2442. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Burney, S. Psychological issues in cancer survivorship. Climacteric 2019, 22, 584–588. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Frederick, N.N.; Lehmann, V.; Ahler, A.; Carpenter, K.; Cherven, B.; Klosky, J.L.; Nahata, L.; Quinn, G.P. Psychosexual functioning in cancer survivorship: What the pediatric oncologist needs to know. Pediatr. Blood Cancer 2023, 70, e30611. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Gough, K.; Bergin, R.J.; Drosdowsky, A.; Aranda, S.; Mileshkin, L.; Jackson, M.; Kinnane, N.; Bernshaw, D.; Juraskova, I.; White, K.; et al. Women with gynaecological cancer awaiting radiotherapy: Self-reported wellbeing, general psychological distress, symptom distress, sexual function, and supportive care needs. Gynecol. Oncol. 2022, 167, 42–50. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.